Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15123509 | 0.93 | MEN1 (0.36) | MEN1KMT2AALDH1A1KDM4EHDAC6 | |
| SCHEMBL15123511 | 0.93 | MEN1 (0.36) | MEN1KMT2AALDH1A1KDM4EHDAC6 | |
| SCHEMBL15123507 | 0.93 | MEN1 (0.36) | MEN1KMT2AALDH1A1KDM4EHDAC6 | |
| SCHEMBL15130510 | 0.90 | ALDH1A1 (0.33) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL903551 | 0.89 | TDP1 (0.38) | MEN1KMT2AALDH1A1CNR1CYP11B1 | |
| SCHEMBL381757 | 0.85 | TDP1 (0.42) | MEN1KMT2AALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL903558 | 0.84 | MEN1 (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL15130519 | 0.81 | MEN1 (0.37) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL903550 | 0.79 | MEN1 (0.43) | MEN1KMT2AALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL15130508 | 0.76 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190268-A1 | BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| WO-2012042123-A1 | BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY | SANOFI (FR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190268-A1 | BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY | BTD, FGB, F13B | MEN1 3269/4885KMT2A 4157/4885ALDH1A1 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.